Alpha Cognition Inc.

Alpha Cognition Inc. is a biopharmaceutical company that develops treatments for patients with neurodegenerative diseases, such as Alzheimer's disease. The company focuses on the commercial manufacturing and sales of ZUNVEYL, an oral tablet formulation. ZUNVEYL was launched on March 19, 2025, and targets large volume nursing homes specializing in Alzheimer's Disease. The company uses an account-based sales team with experience in long-term care, works with Medicare payors, and forms strategic and clinical partnerships with consultant pharmacists and long-term care pharmacies. ZUNVEYL is a patented acetylcholinesterase inhibitor designed for Alzheimer's disease treatment, expected to have minimal gastrointestinal side effects. Its active metabolite differs from donepezil and rivastigmine by binding to neuronal nicotinic receptors, particularly the alpha-7 subtype, which positively affects cognition. Alpha Cognition Inc. also has three additional pre-clinical development programs. These include ZUNVEYL in combination with memantine for moderate-to-severe Alzheimer's disease, and a sublingual formulation of ZUNVEYL for patients with dysphagia. Another program involves ALPHA-1062, a sublingual formulation for treating cognitive impairment associated with mild traumatic brain injury (concussion). The company is also developing ALPHA-0602, ALPHA-0702, and ALPHA-0802, with ALPHA-0702 and ALPHA-0802 referred to as 'Progranulin' and 'Progranulin GEM's'. These latter programs aim to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and spinal muscular atrophy (SMA).